Spearhead Capital Advisors LLC lifted its position in shares of Amgen, Inc. (NASDAQ:AMGN) by 9.1% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 21,477 shares of the medical research company’s stock after purchasing an additional 1,788 shares during the period. Spearhead Capital Advisors LLC’s holdings in Amgen were worth $3,958,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently bought and sold shares of AMGN. Capital Financial Planning LLC purchased a new position in shares of Amgen during the fourth quarter worth about $27,000. Next Capital Management LLC purchased a new position in shares of Amgen during the fourth quarter worth about $33,000. Arbor Wealth Management LLC grew its holdings in shares of Amgen by 154.5% during the second quarter. Arbor Wealth Management LLC now owns 168 shares of the medical research company’s stock worth $31,000 after buying an additional 102 shares during the last quarter. Clarfeld Financial Advisors LLC purchased a new position in shares of Amgen during the fourth quarter worth about $41,000. Finally, C J Advisory Inc purchased a new position in shares of Amgen during the first quarter worth about $40,000. Institutional investors and hedge funds own 77.26% of the company’s stock.
In other news, Director Ronald D. Sugar sold 2,000 shares of Amgen stock in a transaction that occurred on Wednesday, June 5th. The shares were sold at an average price of $175.68, for a total transaction of $351,360.00. Following the completion of the sale, the director now directly owns 16,219 shares in the company, valued at approximately $2,849,353.92. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Over the last quarter, insiders have sold 6,000 shares of company stock valued at $1,077,980. Insiders own 0.25% of the company’s stock.
AMGN traded up $0.01 during trading on Friday, reaching $174.12. The company’s stock had a trading volume of 96,178 shares, compared to its average volume of 2,410,211. Amgen, Inc. has a 52-week low of $166.30 and a 52-week high of $210.19. The firm has a fifty day moving average of $180.28. The company has a market capitalization of $106.24 billion, a P/E ratio of 12.09, a price-to-earnings-growth ratio of 2.15 and a beta of 1.16. The company has a debt-to-equity ratio of 2.71, a current ratio of 2.77 and a quick ratio of 2.53.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, April 30th. The medical research company reported $3.56 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.45 by $0.11. Amgen had a return on equity of 71.02% and a net margin of 34.00%. The company had revenue of $5.56 billion for the quarter, compared to analyst estimates of $5.55 billion. During the same quarter in the previous year, the company earned $3.47 EPS. The firm’s revenue for the quarter was up .1% compared to the same quarter last year. As a group, research analysts anticipate that Amgen, Inc. will post 13.85 EPS for the current year.
A number of equities analysts recently issued reports on AMGN shares. BidaskClub raised Westport Fuel Systems from a “hold” rating to a “buy” rating in a report on Friday, July 12th. Credit Suisse Group started coverage on Regeneron Pharmaceuticals in a report on Monday, May 20th. They set a “neutral” rating and a $336.00 price target on the stock. Morgan Stanley set a $70.00 price target on Edison International and gave the stock a “hold” rating in a report on Monday, July 15th. Citigroup raised Gilead Sciences from a “neutral” rating to a “buy” rating and set a $66.80 price target on the stock in a report on Wednesday, May 22nd. Finally, Cantor Fitzgerald reissued a “hold” rating and set a $41.00 price target on shares of Mylan in a report on Monday, April 1st. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and eleven have given a buy rating to the company. Amgen presently has a consensus rating of “Hold” and an average price target of $208.10.
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
Further Reading: Swap
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.